818 A.2d 914 (Del. 2003)
NCS Healthcare, Inc., a Delaware corporation headquartered in Beachwood, Ohio, provided pharmacy services to long-term care institutions.1 Its capital structure included Class A common stock with one vote per share and Class B common stock with ten votes per share.2 Jon H. Outcalt, NCS chairman, and Kevin B. Shaw, NCS president and CEO, together held a majority of the voting power through their Class B shares.3 By early 2001, NCS had defaulted on approximately $350 million in debt, its stock traded between $0.09 and $0.50 per share, and the company faced the prospect of bankruptcy with little or no recovery for stockholders.4
Beginning in late 1999, NCS began to explore strategic alternatives after changes in government reimbursements harmed its business.5 NCS retained UBS Warburg in February 2000 to solicit acquirers and investors, contacting over fifty entities.6 NCS later retained Brown, Gibbons, Lang & Company as its exclusive financial advisor.7 Omnicare, Inc., a Delaware corporation and NCS competitor with annual sales exceeding $2.1 billion, proposed only asset purchases in bankruptcy at prices that would not fully repay NCS creditors.8 In January 2002, Genesis Health Ventures, Inc., a Pennsylvania corporation, was contacted through the Ad Hoc Committee of NCS noteholders.9 Genesis insisted on exclusivity and lock-up protections because of its prior loss of a transaction to Omnicare.10
In March 2002, NCS formed an independent committee consisting of directors Boake A. Sells and Richard L. Osborne.11 On May 16, 2002, Genesis stated it would not participate as a stalking horse.12 Negotiations produced improving offers from Genesis that included full repayment of senior debt, payment at par for subordinated notes, and $24 million in Genesis stock for NCS common stockholders.13 On June 27, 2002, NCS executed an exclusivity agreement with Genesis.14 The agreement was extended through July 31, 2002.15 On July 26, 2002, Omnicare submitted a letter proposing to retire NCS debt at par plus accrued interest and pay $3 cash per NCS share, but the proposal remained conditioned on due diligence.16
On July 27, 2002, Genesis delivered a final proposal requiring execution of definitive documents by midnight on July 28.17 The proposal included a Section 251(c) provision mandating a stockholder vote on the merger even if the NCS board withdrew its recommendation.18 The proposal also included a $6 million termination fee and no effective fiduciary out clause.19 On July 28, 2002, the NCS board approved the merger agreement and authorized voting agreements with Outcalt and Shaw.20 Those agreements irrevocably committed the two stockholders to vote their shares in favor of the Genesis merger and granted Genesis an irrevocable proxy.21 The agreements were executed the same day.22
On July 29, 2002, Omnicare publicly announced a revised proposal and later commenced a tender offer at $3.50 per share.23 On October 6, 2002, Omnicare delivered an irrevocable commitment to acquire all NCS shares for $3.50 cash.24 On October 21, 2002, the NCS board withdrew its recommendation in favor of the Genesis merger.25 On October 25, 2002, the Court of Chancery dismissed Omnicare's fiduciary duty claims for lack of standing.2627 On October 29, 2002, the court adjudicated the merits of the voting agreements.28 On November 22, 2002, the court denied a preliminary injunction against the merger.29 Consolidated appeals followed to the Delaware Supreme Court.30
Whether the NCS board of directors' decision to approve the Genesis merger agreement containing a Section 251(c) provision and to enter into related voting agreements with Outcalt and Shaw is subject to enhanced judicial scrutiny?31
When a board adopts defensive measures to protect a merger agreement, those measures are subject to enhanced judicial scrutiny under Unocal.32 This applies even if the merger does not involve a change of control.33 The board must demonstrate reasonable grounds for believing a danger to corporate policy and effectiveness existed.34 The response must be reasonable in relation to the threat and not preclusive or coercive.35
Yes. The NCS board approved the Genesis merger agreement containing the Section 251(c) provision and authorized the voting agreements with Outcalt and Shaw.36 These actions were taken in response to Genesis's insistence on lock-up protections to avoid losing the transaction to a competitor such as Omnicare.37 The measures were designed to guarantee stockholder approval of the Genesis deal regardless of any subsequent superior proposal.38
The combination of the voting agreements locking up majority voting power and the Section 251(c) requirement therefore triggered Unocal enhanced scrutiny as defensive devices protecting the merger.
The NCS board's decision to approve the Genesis merger agreement and related voting agreements is subject to enhanced judicial scrutiny under Unocal.39
Whether the combination of the Section 251(c) provision in the NCS-Genesis merger agreement, the voting agreements executed by Outcalt and Shaw, and the absence of an effective fiduciary out clause constitutes preclusive and coercive defensive measures?40
Defensive measures protecting a merger agreement are preclusive if they deprive stockholders of the right to receive all tender offers or fundamentally restrict proxy contests.41 Such measures are coercive if aimed at forcing stockholders to accept a management-sponsored alternative.42 Draconian measures are invalid under Unocal.43
Yes. The Section 251(c) provision required submission of the Genesis merger to a stockholder vote even after the NCS board withdrew its recommendation.44 The voting agreements irrevocably committed Outcalt and Shaw, who held majority voting power, to approve the merger and granted Genesis an irrevocable proxy.45 The absence of an effective fiduciary out clause prevented the board from accepting Omnicare's superior proposal.46
As detailed in the established facts, these measures operated together to make approval of the Genesis transaction a fait accompli, rendering any competing transaction mathematically impossible and realistically unattainable.47
The combination of the Section 251(c) provision, the voting agreements, and the absence of an effective fiduciary out clause constitutes preclusive and coercive defensive measures that are invalid and unenforceable.48
Whether the NCS board had authority to agree to an absolute lock-up of the Genesis merger transaction without retaining the ability to consider a superior proposal from Omnicare or any other bidder?49
No. The NCS board agreed to the Genesis merger agreement with the Section 251(c) provision and no effective fiduciary out clause, together with the voting agreements, creating an absolute lock-up.52 In the established facts, the board later withdrew its recommendation after Omnicare delivered an irrevocable $3.50 per share cash proposal that was superior for stockholders.53 The lock-up prevented the board from accepting or negotiating that proposal despite its continuing fiduciary obligations to minority stockholders.54 The board therefore lacked authority to disable itself from responding to the superior offer.55
The NCS board did not have authority to agree to an absolute lock-up of the Genesis merger without retaining the ability to consider a superior proposal.56
Related opinions on this issue
Joined by Justice Steele
Chief Justice Veasey dissented.57 He argued that the NCS board's decision to lock up the Genesis transaction was a quintessential disinterested and informed board decision reached in good faith amid insolvency and creditor pressure where Genesis was the only viable bidder.58 The lock-up was the sine qua non of the only value-enhancing transaction available.59
The majority's per se invalidation of such measures without a fiduciary out represents an unwise extension of precedent that should be confined to these unique facts.60
Justice Steele dissented separately.61 He argued that the board acted selflessly pursuant to a careful fair process and determined in good faith that the benefits flowing from the merger agreement containing reasonable deal protection provisions outweighed any speculative benefits from entertaining a putative higher offer.62 Delaware law mandates deference under the business judgment rule to such a decision free from self-interest made with due care and in good faith.63
Courts should not second-guess the board's cost-benefit analysis by invalidating an otherwise valid contract.64
Whether Omnicare had standing to assert fiduciary duty claims arising from board actions that occurred before Omnicare acquired its NCS shares?65
A plaintiff lacks standing to assert fiduciary duty claims based on board actions that preceded the plaintiff's acquisition of shares.66
No. Omnicare purchased its NCS shares on July 30, 2002, after the NCS board had approved the Genesis merger agreement and voting agreements on July 28, 2002.67 The Court of Chancery dismissed Omnicare's fiduciary duty claims for lack of standing. The Supreme Court dismissed the appeal of that standing decision as moot after resolving the fiduciary duty claims on the merits in the class action.68
Omnicare lacked standing to assert fiduciary duty claims arising from board actions that occurred before it acquired its NCS shares.69